26-Dec-2025
Medicare pilot programs aim to reduce prescription drug spend
Seeking Alpha News (Wed, 24-Dec 9:29 AM ET)
Gilead to buy Repare Thera’s cancer candidate for up to $30M
Seeking Alpha News (Wed, 24-Dec 7:19 AM ET)
MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
TipRanks (Tue, 23-Dec 10:16 AM ET)
Business Wire (Mon, 22-Dec 7:00 AM ET)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Yolowire (Mon, 22-Dec 6:53 AM ET)
Business Wire (Mon, 22-Dec 2:30 AM ET)
Business Wire (Mon, 22-Dec 2:30 AM ET)
Business Wire (Thu, 18-Dec 2:30 AM ET)
Business Wire (Mon, 15-Dec 4:29 PM ET)
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Astrazeneca PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AZN.
As of December 26, 2025, AZN stock price climbed to $92.90 with 1,539,811 million shares trading.
AZN has a beta of 0.29, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.04 to the broad based SPY ETF.
AZN has a market cap of $287.83 billion. This is considered a Mega Cap stock.
Last quarter Astrazeneca PLC - American Depositary Shares reported $15 billion in Revenue and $1.19 earnings per share. This beat revenue expectation by $386 million and exceeded earnings estimates by $.05.
In the last 3 years, AZN traded as high as $94.02 and as low as $60.47.
The top ETF exchange traded funds that AZN belongs to (by Net Assets): QQQ, QQQM, PVAL, CGGO, TQQQ.
AZN has outperformed the market in the last year with a price return of +42.0% while the SPY ETF gained +16.0%. AZN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.9% and +3.4%, respectively, while the SPY returned +4.6% and +1.5%, respectively.
AZN support price is $91.32 and resistance is $93.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN shares will trade within this expected range on the day.